STLEUIS II
Research type
Research Study
Full title
Smartphone Twelve Lead ECG Utility In ST-Elevation Myocardial Infarction II
IRAS ID
349441
Contact name
Muzahir H Tayebjee
Contact email
Sponsor organisation
AliveCor, Inc.
Clinicaltrials.gov Identifier
Duration of Study in the UK
0 years, 9 months, 31 days
Research summary
The main goal of this study is to find out if the AliveCor 12L ECG System can effectively replace a standard 12-lead ECG for detecting a specific type of heart attack called STEMI in patients who come in with chest discomfort. Validating our device can help provide a timelier diagnosis and treatment and expand its use in various underserved settings.
STEMI occurs when a coronary artery is completely blocked, which can happen due to blood clots or other factors. This type of heart attack requires urgent treatment to restore blood flow. Recently, AliveCor has introduced a new device that can record heart activity using just five leads in a single-cable design, allowing it to create a full 12-lead ECG quickly and easily.
The study will involve adult patients (18 and older) who experience chest discomfort or for whom a STEMI protocol has been initiated at one of the hospitals participating in the research. These hospitals have been chosen for their expertise in treating heart conditions and conducting clinical studies. We expect to enroll enough participants within 16 weeks at each hospital. Importantly, patients won't need any follow-up visits after their initial screening for this study.
REC name
North West - Greater Manchester Central Research Ethics Committee
REC reference
25/NW/0043
Date of REC Opinion
29 Apr 2025
REC opinion
Further Information Favourable Opinion